-+ 0.00%
-+ 0.00%
-+ 0.00%

BriaCell Presents Bria-IMT Phase 2 Survival Data in Metastatic Breast Cancer

PUBT·11/18/2026 19:23:27
语音播报
BriaCell Presents Bria-IMT Phase 2 Survival Data in Metastatic Breast Cancer
  • BriaCell Therapeutics highlighted its ongoing pivotal Phase 3 trial of Bria-IMT with a checkpoint inhibitor in metastatic breast cancer.
  • The trial targets overall survival, with an interim efficacy analysis at 144 events that could support full approval.
  • Phase 2 median overall survival reached 16.6 months with the Phase 3 formulation and treatment sequence.
  • Median progression-free survival favored the selected formulation at 3.6 months versus 2.6 months for the alternative formulation.
  • Next-generation candidates Bria-BRES+ and Bria-PROS+ have open investigational new drug applications, with patient recruitment underway.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief on November 18, 2026, and is solely responsible for the information contained therein.